Foundation Frontiers: Advanced Breast Cancer - Updates to HR+/HER2- Treatment Landscape
Outlook for HR+/HER2- advanced breast cancer treatment
HER2+ Metastatic Breast Cancer: Standard of Care Therapies
Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer
Current and future HER2+, HR- metastatic breast cancer treatment approaches
Management of premenopausal HR+/HER2- breast cancer with micro-metastasis
HER2 Positive Breast Cancer: Everything You Must Know
#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study
Moving the Needle in ER-Positive/HER2-Negative Metastatic Breast Cancer: Exploring SERD Strategie...
Current Treatment Options for Patients With HER2-Positive Metastatic Breast Cancer
Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer
Important considerations in the management of HR+, HER2-negative early breast cancer
Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors
Dr Mukesh | Redefining the standard of care for postmenopausal HR+Her2 aBc
Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer
Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer pts
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer
Dr. Varella on the Results of MONALEESA-7 in HR+/HER2- Breast Cancer
What Treatments Are Available for HER2-Positive Metastatic Breast Cancer?